Fig 4. CBP-93872 reduces the levels of oxaliplatin-, cisplatin- and gemcitabine-induced phosphorylations of ATR and Chk1.

(A, B) HT29 cells were treated with oxaliplatin (30 μM) (A), or cisplatin (30 μM) (B) in the presence of absence of CBP-93872 (50 μM). Cells were harvested at the times indicated, and total cell extracts were subjected to immmunoblotting using indicated antibodies. (C) Panc-1 cells were treated with gemcitabine (0.1 μM), in the presence or absence of CBP-93872 (200 μM).